Sophiris Bio, Inc. (SPHS) Expected to Announce Earnings of -$0.11 Per Share
Wall Street analysts forecast that Sophiris Bio, Inc. (NASDAQ:SPHS) will report earnings per share of ($0.11) for the current quarter, according to Zacks. Zero analysts have made estimates for Sophiris Bio’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.12). Sophiris Bio reported earnings per share of ($0.07) in the same quarter last year, which suggests a negative year over year growth rate of 57.1%. The company is expected to announce its next earnings report on Monday, March 26th.
According to Zacks, analysts expect that Sophiris Bio will report full-year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.24). For the next fiscal year, analysts expect that the firm will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.58) to ($0.35). Zacks’ EPS averages are an average based on a survey of analysts that cover Sophiris Bio.
A number of equities research analysts recently weighed in on SPHS shares. HC Wainwright set a $6.00 target price on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Friday, August 11th. Maxim Group set a $6.00 target price on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Monday, August 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Sophiris Bio has a consensus rating of “Buy” and a consensus target price of $6.25.
Sophiris Bio (NASDAQ SPHS) traded down $0.03 on Wednesday, hitting $2.06. 121,889 shares of the company were exchanged, compared to its average volume of 285,360. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $3.24.
An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. bought a new stake in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio as of its most recent SEC filing. Institutional investors own 5.77% of the company’s stock.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.